GLOBAL BIOENERGIES SA(EPA:ALGBE) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALGBE. ALGBE was compared to 63 industry peers in the Chemicals industry. While ALGBE seems to be doing ok healthwise, there are quite some concerns on its profitability. ALGBE has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGBE has reported negative net income.

ALGBE had a negative operating cash flow in the past year.

ALGBE had negative earnings in each of the past 5 years.

In the past 5 years ALGBE always reported negative operating cash flow.

1.2 Ratios

ALGBE has a worse Return On Assets (-53.94%) than 88.89% of its industry peers.

ALGBE's Return On Equity of -159.25% is on the low side compared to the rest of the industry. ALGBE is outperformed by 88.89% of its industry peers.

		Industry Rank	Sector Rank
ROA	-53.94%
ROE	-159.25%
ROIC	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALGBE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGBE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALGBE remains at a similar level compared to 1 year ago.

Compared to 5 years ago, ALGBE has more shares outstanding

ALGBE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that ALGBE is in the distress zone and has some risk of bankruptcy.

ALGBE has a worse Altman-Z score (-0.18) than 82.54% of its industry peers.

ALGBE has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.

Looking at the Debt to Equity ratio, with a value of 1.02, ALGBE is doing worse than 76.19% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	1.02
Debt/FCF	N/A
Altman-Z	-0.18

ROIC/WACCN/A

WACC7.28%

2.3 Liquidity

ALGBE has a Current Ratio of 2.93. This indicates that ALGBE is financially healthy and has no problem in meeting its short term obligations.

ALGBE's Current ratio of 2.93 is fine compared to the rest of the industry. ALGBE outperforms 79.37% of its industry peers.

A Quick Ratio of 2.79 indicates that ALGBE has no problem at all paying its short term obligations.

ALGBE's Quick ratio of 2.79 is amongst the best of the industry. ALGBE outperforms 88.89% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.93
Quick Ratio	2.79

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGBE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.58%, which is quite impressive.

Looking at the last year, ALGBE shows a very negative growth in Revenue. The Revenue has decreased by -88.90% in the last year.

ALGBE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.17% yearly.

EPS 1Y (TTM)32.58%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.12%

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.95%

Revenue growth 5Y25.17%

Sales Q2Q%-85.06%

3.2 Future

The Earnings Per Share is expected to decrease by -5.13% on average over the next years.

The Revenue is expected to grow by 0.48% on average over the next years.

EPS Next Y21.05%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGBE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALGBE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALGBE's earnings are expected to decrease with -5.13% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALGBE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLOBAL BIOENERGIES SA

EPA:ALGBE (3/7/2025, 7:00:00 PM)

1.248

0 (-0.16%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)09-17 2024-09-17

Earnings (Next)09-08 2025-09-08

Inst Owners1.07%

Inst Owner ChangeN/A

Ins Owners2.57%

Ins Owner ChangeN/A

Market Cap22.68M

Analysts84.44

Price Target3.37 (170.03%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-25%

EPS NY rev (3m)-25%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-22.22%

Revenue NY rev (3m)-22.22%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	46.66
P/FCF	N/A
P/OCF	N/A
P/B	4.91
P/tB	5.13
EV/EBITDA	N/A

EPS(TTM)-0.32

EYN/A

EPS(NY)-0.23

Fwd EYN/A

FCF(TTM)-0.26

FCFYN/A

OCF(TTM)-0.22

OCFYN/A

SpS0.03

BVpS0.25

TBVpS0.24

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-53.94%
ROE	-159.25%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-54.57%

ROA(5y)-48.79%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	1.02
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	21.61%
Cap/Sales	133.04%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.93
Quick Ratio	2.79
Altman-Z	-0.18

F-Score2

WACC7.28%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)32.58%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.12%

EPS Next Y21.05%

EPS Next 2Y-5.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-88.9%

Revenue growth 3Y52.95%

Revenue growth 5Y25.17%

Sales Q2Q%-85.06%

Revenue Next Year0.97%

Revenue Next 2Y0.48%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y26.33%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year32.03%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y49.53%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y51.24%

OCF growth 3YN/A

OCF growth 5YN/A

GLOBAL BIOENERGIES SA (ALGBE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens